Michael Rowley
Senior Vice President, Drug Discovery Services Europe
Pharmaron
United Kingdom
Biography
Dr. Michael Rowley is Senior Vice President, Drug Discovery Services Europe. He joined Pharmaron in March 2017 and brings 28 years’ experience in Drug Discovery. In 1988, he joined Merck Sharp and Dohme in the UK as a medicinal chemist, then in 2000 moved to become responsible for Medicinal Chemistry and DMPK at IRBM (the MSD research site in Rome), working in the areas of antivirals and cancer. It was during this time that the group in Rome discovered Isentress™ for HIV, Grazoprevir (part of the dual combination Zepatier™ for HCV) and Zejula™ for ovarian cancer. He joined AstraZeneca in Mölndal, Sweden in summer 2009 as Head of Medicinal Chemistry for the Cardiovascular/Gastrointestinal Therapeutic Area. Mike returned to MSD in early 2012 in the role as Chemistry Leader, Lucerne responsible for scientific strategy for MRL Discovery Chemistry. Dr. Rowley obtained his MA and PhD in Cambridge, UK followed by two years as a postdoc at Harvard. He has published over 130 papers and 40 patent applications, is a Fellow of the Royal Society of Chemistry, an ACS Hero of Chemistry and has been inducted into the ACS Medicinal Chemistry Hall of Fame.
Research Interest
Dr. Michael Roeley has research interest in drug discovery, Medicinal Chemistry, Oncology and Therapeutics and Business Management.
